GI Esophageal / Gastric

- Localized
  - HER 2+
    - 1st Line
    - No Trials Currently Available
  - HER 2-
    - 1st Line
    - IRB# 15349
      Keynote-181
      A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy
    - 2nd Line
    - IRB# 15706
      EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
  - 2nd Line
- Metastatic
  - HER 2+
    - 1st Line
    - IRB# 15349
      Keynote-181
      A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy
  - HER 2-
    - 1st Line
    - IRB# 15706
      EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction
    - 2nd Line

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

11/15/2016
www.ohsu.edu/cancer